CL2011000283A1 - Preparado combinado polifasico que comprende 4 fases con unidades de dosis que contienen primera : <3 mg de estradiol (et), segunda: unas con <2 mg de et y 2 mg de dienogest (dg) y otras con <2 mg de et y 3 mg de dg, tercera: <1 mg de et y cuarta: placebo; util para la anticoncepcion oral y tratar para la hemorragia uterina disfuncional. - Google Patents
Preparado combinado polifasico que comprende 4 fases con unidades de dosis que contienen primera : <3 mg de estradiol (et), segunda: unas con <2 mg de et y 2 mg de dienogest (dg) y otras con <2 mg de et y 3 mg de dg, tercera: <1 mg de et y cuarta: placebo; util para la anticoncepcion oral y tratar para la hemorragia uterina disfuncional.Info
- Publication number
- CL2011000283A1 CL2011000283A1 CL2011000283A CL2011000283A CL2011000283A1 CL 2011000283 A1 CL2011000283 A1 CL 2011000283A1 CL 2011000283 A CL2011000283 A CL 2011000283A CL 2011000283 A CL2011000283 A CL 2011000283A CL 2011000283 A1 CL2011000283 A1 CL 2011000283A1
- Authority
- CL
- Chile
- Prior art keywords
- dienogest
- estradiol
- combined
- placebo
- phases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Preparado combinado polifásico para la anticoncepción oral y la terapia oral de hemorragia uterina disfuncional que contiene estradiol y dienogest en diferentes cantidades (Div. Sol.2751-06).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05022324A EP1787649B1 (de) | 2005-10-13 | 2005-10-13 | Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011000283A1 true CL2011000283A1 (es) | 2011-07-08 |
Family
ID=35811580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000283A CL2011000283A1 (es) | 2005-10-13 | 2011-02-10 | Preparado combinado polifasico que comprende 4 fases con unidades de dosis que contienen primera : <3 mg de estradiol (et), segunda: unas con <2 mg de et y 2 mg de dienogest (dg) y otras con <2 mg de et y 3 mg de dg, tercera: <1 mg de et y cuarta: placebo; util para la anticoncepcion oral y tratar para la hemorragia uterina disfuncional. |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP1787649B1 (es) |
JP (2) | JP5735200B2 (es) |
KR (2) | KR20080065651A (es) |
CN (1) | CN101312733A (es) |
AR (1) | AR056694A1 (es) |
AT (2) | ATE424828T1 (es) |
CA (1) | CA2623024C (es) |
CL (1) | CL2011000283A1 (es) |
CY (2) | CY1110321T1 (es) |
DE (2) | DE502005006837D1 (es) |
DK (2) | DK1787649T3 (es) |
DO (1) | DOP2006000221A (es) |
ES (2) | ES2322479T3 (es) |
HR (1) | HRP20090256T1 (es) |
ME (1) | ME01056B (es) |
PE (2) | PE20100090A1 (es) |
PL (2) | PL1787649T3 (es) |
PT (2) | PT1787649E (es) |
SI (2) | SI1787649T1 (es) |
TW (2) | TWI328453B (es) |
UY (1) | UY29861A1 (es) |
WO (1) | WO2007042296A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004019743B4 (de) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
ES2322479T3 (es) * | 2005-10-13 | 2009-06-22 | Bayer Schering Pharma Aktiengesellschaft | Utilizacion de valerato de estradiol en combinacion con dienogest para la terapia por via oral de la hemorragia uterina disfuncional, en union con una contracepcion oral. |
US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4429374C1 (de) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
AU4043597A (en) * | 1996-07-26 | 1998-02-20 | American Home Products Corporation | Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
US6251956B1 (en) | 1998-08-20 | 2001-06-26 | Ortho Pharmaceutical Corporation | Combination progestin oral contraceptive regimen |
EP1462106A1 (en) * | 2003-03-28 | 2004-09-29 | Pantarhei Bioscience B.V. | Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders |
DE102004019743B4 (de) * | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
ES2322479T3 (es) * | 2005-10-13 | 2009-06-22 | Bayer Schering Pharma Aktiengesellschaft | Utilizacion de valerato de estradiol en combinacion con dienogest para la terapia por via oral de la hemorragia uterina disfuncional, en union con una contracepcion oral. |
-
2005
- 2005-10-13 ES ES05022324T patent/ES2322479T3/es active Active
- 2005-10-13 SI SI200530672T patent/SI1787649T1/sl unknown
- 2005-10-13 PT PT05022324T patent/PT1787649E/pt unknown
- 2005-10-13 DK DK05022324T patent/DK1787649T3/da active
- 2005-10-13 DE DE502005006837T patent/DE502005006837D1/de active Active
- 2005-10-13 EP EP05022324A patent/EP1787649B1/de not_active Revoked
- 2005-10-13 PL PL05022324T patent/PL1787649T3/pl unknown
- 2005-10-13 AT AT05022324T patent/ATE424828T1/de active
- 2005-10-13 ME MEP-2009-171A patent/ME01056B/me unknown
-
2006
- 2006-10-12 PL PL06806225T patent/PL1933843T3/pl unknown
- 2006-10-12 CA CA2623024A patent/CA2623024C/en active Active
- 2006-10-12 JP JP2008534936A patent/JP5735200B2/ja active Active
- 2006-10-12 WO PCT/EP2006/009867 patent/WO2007042296A1/de active Application Filing
- 2006-10-12 EP EP06806225A patent/EP1933843B1/de active Active
- 2006-10-12 CN CNA2006800381810A patent/CN101312733A/zh active Pending
- 2006-10-12 AT AT06806225T patent/ATE497387T1/de active
- 2006-10-12 PE PE2009001256A patent/PE20100090A1/es not_active Application Discontinuation
- 2006-10-12 PE PE2006001241A patent/PE20070555A1/es not_active Application Discontinuation
- 2006-10-12 KR KR1020087011203A patent/KR20080065651A/ko not_active Application Discontinuation
- 2006-10-12 DK DK06806225.6T patent/DK1933843T3/da active
- 2006-10-12 TW TW095137564A patent/TWI328453B/zh active
- 2006-10-12 ES ES06806225T patent/ES2360302T3/es active Active
- 2006-10-12 KR KR1020107014574A patent/KR101218872B1/ko active IP Right Grant
- 2006-10-12 PT PT06806225T patent/PT1933843E/pt unknown
- 2006-10-12 SI SI200630991T patent/SI1933843T1/sl unknown
- 2006-10-12 DE DE502006008853T patent/DE502006008853D1/de active Active
- 2006-10-13 AR ARP060104489A patent/AR056694A1/es not_active Application Discontinuation
- 2006-10-13 UY UY29861A patent/UY29861A1/es not_active Application Discontinuation
- 2006-10-13 DO DO2006000221A patent/DOP2006000221A/es unknown
-
2007
- 2007-01-09 TW TW096100872A patent/TW200829255A/zh unknown
-
2009
- 2009-05-05 HR HR20090256T patent/HRP20090256T1/xx unknown
- 2009-06-11 CY CY20091100621T patent/CY1110321T1/el unknown
-
2011
- 2011-02-10 CL CL2011000283A patent/CL2011000283A1/es unknown
- 2011-05-02 CY CY20111100422T patent/CY1111406T1/el unknown
-
2012
- 2012-11-19 JP JP2012253067A patent/JP2013047269A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6160297A2 (es) | Uso de valerato de estradiol o 17beta-estradiol en combinacion de dienogest en una terapia oral para mantener y/o incrementar la libido femenina | |
NO20062945L (no) | Forlenget anvendelseskombinasjon omfattende ostrogener og progestiner | |
AR049112A1 (es) | Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual | |
SG152257A1 (en) | Topical preparation containing ambroxol | |
HUP0300335A2 (hu) | 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
Morad et al. | Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53 | |
PE20061415A1 (es) | Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato | |
CL2011000283A1 (es) | Preparado combinado polifasico que comprende 4 fases con unidades de dosis que contienen primera : <3 mg de estradiol (et), segunda: unas con <2 mg de et y 2 mg de dienogest (dg) y otras con <2 mg de et y 3 mg de dg, tercera: <1 mg de et y cuarta: placebo; util para la anticoncepcion oral y tratar para la hemorragia uterina disfuncional. | |
CR7611A (es) | Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona | |
ES2348038T3 (es) | Preparado polifasico para la contracepcion sobre la base de un estrogeno natural. | |
PE20080400A1 (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas | |
AR049196A1 (es) | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona | |
BRPI0408944A (pt) | método para fornecer um benefìcio de redução de esteróide com um inibidor de ciclooxigenase-2 e composições com este | |
BR0111051A (pt) | Produto farmacêutico e dose farmacêutica diária para administração a um paciente, regime de dose prover um efeito anti-androgênico e um efeito anti-estrogênico em um paciente, uso de um composto e de tamoxifeno ou de um sal ou solvato farmaceuticamente aceitável destes, e, método para prover um efeito anti-androgênico em um paciente | |
CL2008000999A1 (es) | Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres. | |
WO2002074315A8 (de) | Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie | |
BRPI0504082A (pt) | emulsões refrescantes medicinais | |
BRPI0606724A2 (pt) | preparação farmacêutica para contracepção | |
CR11211A (es) | Estratienos 8-beta-sustituidos como estrogenos de accion selectiva | |
EA200900829A1 (ru) | Фармацевтический препарат для уменьшения эндометриоза | |
BR0313305A (pt) | Agente analgésico para indivìduos recém-nascidos ou fetais | |
BRPI0511931A (pt) | uso de 7-t-butoxiiminometilcamptotecina para a preparação de um medicamento para o tratamento de neoplasmas uterinos | |
PE20070769A1 (es) | Procedimiento para la produccion de una preparacion farmaceutica monofasica para la terapia oral de la hemorragia uterina disfuncional | |
CY1112775T1 (el) | Χρηση βαλεριανικης οιστραδιολης σε συνδυασμο με dienogest για την απο του στοματος θεραπεια της δυσλειτουργικης αιμορραγιας της μητρας σε ενοτητα με αντισυλληψη απο του στοματος | |
Creatsas et al. | Noncontraceptive Benefits of 17β-Estradiol COCs During Adolescence |